The Behavioral Effects of the Antidepressant Tianeptine Require the Mu-Opioid Receptor.
Benjamin Adam SamuelsKatherine M NautiyalAndrew C KruegelMarjorie R LevinsteinValerie M MagalongMadalee M GassawaySteven G GrinnellJaena HanMichael A AnsonoffJohn E PintarJonathan A JavitchDalibor SamesRené HenPublished in: Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology (2017)
Depression is a debilitating chronic illness that affects around 350 million people worldwide. Current treatments, such as selective serotonin reuptake inhibitors, are not ideal because only a fraction of patients achieve remission. Tianeptine is an effective antidepressant with a previously unknown mechanism of action. We recently reported that tianeptine is a full agonist at the mu opioid receptor (MOR). Here we demonstrate that the acute and chronic antidepressant-like behavioral effects of tianeptine in mice require MOR. Interestingly, while tianeptine also produces many opiate-like behavioral effects such as analgesia and reward, it does not lead to tolerance or withdrawal. Furthermore, the primary metabolite of tianeptine (MC5), which has a longer half-life, mimics the behavioral effects of tianeptine in a MOR-dependent fashion. These results point to the possibility that MOR and its downstream signaling cascades may be novel targets for antidepressant drug development.
Keyphrases
- major depressive disorder
- pain management
- end stage renal disease
- chronic pain
- ejection fraction
- newly diagnosed
- chronic kidney disease
- liver failure
- bipolar disorder
- peritoneal dialysis
- type diabetes
- drug induced
- depressive symptoms
- prognostic factors
- metabolic syndrome
- skeletal muscle
- sleep quality
- physical activity
- rheumatoid arthritis
- insulin resistance
- high fat diet induced
- intensive care unit
- disease activity
- ulcerative colitis
- postoperative pain